ArticleiScience2025
Evaluating cadonilimab efficacy and safety in retrospective first line treatment for advanced pancreatic cancer.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease with limited treatment options. In this single-center retrospective study, we compared two first-line regimens in 52 patients with metastatic PDAC. Patients received either gemcitabine with nab-paclitaxel or the same chemotherapy combined with cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4. Propensity score matching was applied to balance baseline characteristics. The results indicated that the addition of cadonilimab was associated with an improved median progression-free survival compared to chemotherapy alone. The safety profile of the combination regimen was manageable, with treatment-related adverse events comparable between groups. These findings provide evidence that integrating cadonilimab into standard chemotherapy may enhance treatment outcomes in advanced PDAC, highlighting a potential therapeutic strategy that merits further evaluation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.